Size-shrinking nanoparticles with high drug-protein payload for efficient, non-invasive treatment of corneal neovascularization.

Xiaoling Xie, Zhenyang Xiang, Ruhui Yang, Xuanlu Wu, Jinyu Guo, Ruolin Fang, Xingjie Zan, Wenjuan Huang, Yuhua Tong

Abstract read

In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaoling XieWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, Zhejiang, China.

Zhenyang XiangTaizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China.

Ruhui YangWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, Zhejiang, China.

Xuanlu WuThe First Hospital Affiliated to China Medical University, Shenyang, 110000, Liaoning, China.

Jinyu GuoWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, Zhejiang, China.

Ruolin FangJinhua Joint Training Base, Zhejiang Chinese Medical University, Jinhua, 321017, Zhejiang, China.

Xingjie ZanWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, Zhejiang, China. zanxj@ucas.ac.cn.

Wenjuan HuangTaizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China. huangwj5388@enzemed.com.

Yuhua TongDepartment of Ophthalmology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000, Zhejiang, China. yuhuatong@wmu.edu.cn.

Funding

National Natural Science Foundation of China 82401294Zhejiang Provincial Medical and Health Science and Technology Project 2025KY426

6 · The paper itself

Abstract

Corneal neovascularization (CNV) is one of the leading causes of corneal blindness, affecting millions of people worldwide. Anti-vascular endothelial growth factor agents, such as Bevacizumab (Beva), offer high specificity and low side effects. However, their limited ability to penetrate the corneal barrier necessitates invasive administration, significantly restricting their clinical application. Herein, we engineered (Beva&C₂G₂R₉)@Zn nanoparticles formed by co-assembling Beva, C₂G₂R₉ peptide and Zn

Indexed as

Angiogenesis InhibitorsBevacizumabCorneal NeovascularizationNanoparticlesAnimalsCell MovementCorneaDrug CarriersHumansHuman Umbilical Vein Endothelial CellsMaleParticle SizePeptidesRatsRats, Sprague-DawleyZincAngiogenesis InhibitorsBevacizumabDrug CarriersPeptidesZincBiobarrierCorneal neovascularizationNon-invasive deliveryProtein deliverySize effect

Identifiers

PMID42432700

DOI10.1186/s12951-026-04775-7

PMCPMC13640248

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.